MicroRNA-421 is a new potential diagnosis biomarker with higher sensitivity and specificity than carcinoembryonic antigen and cancer antigen 125 in gastric cancer

Biomarkers. 2015 Feb;20(1):58-63. doi: 10.3109/1354750X.2014.992812. Epub 2014 Dec 16.

Abstract

Context: The sensitivity and specificity of blood microRNA-421 (miR-421) as a gastric cancer (GC) biomarker has not been determined.

Objective: To investigate the diagnostic value of blood miR-421 as GC biomarker.

Materials and methods: miR-421 in serum and peripheral blood mononuclear cells (PBMCs) of 90 GC patients and 90 controls was detected by quantitative real-time PCR. The correlation of miR-421 to GC clinicopathological features as well as the diagnostic value of miR-421 comparing to carcinoembryonic antigen (CEA) and cancer antigen 125 (CA-125) were analyzed.

Results: miR-421 increased significantly in GC patients than in controls. miR-421 in either serum or PBMCs had higher sensitivity and specificity than CEA and CA-125 in GC diagnosis. The GC positive prediction rates of miR-421 were also significantly higher than those of CEA and CA-125.

Discussion and conclusions: miR-421 in serum or PBMCs may be a new potential diagnostic biomarker for GC.

Keywords: Cancer antigen 125; MicroRNA-421; carcinoembryonic antigen; gastric cancer; tumor marker.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CA-125 Antigen / blood*
  • Carcinoembryonic Antigen / blood*
  • Case-Control Studies
  • Female
  • Humans
  • Male
  • MicroRNAs / blood*
  • ROC Curve
  • Stomach Neoplasms / blood*
  • Stomach Neoplasms / diagnosis

Substances

  • CA-125 Antigen
  • Carcinoembryonic Antigen
  • MIRN421 microRNA, human
  • MicroRNAs